I-Corps: A novel catheter for interventional cardiology

I-Corps：用于介入心脏病学的新型导管

• 批准号: 2300450
• 负责人: Jeffrey Lipton
• 金额: $ 5万
• 依托单位: University of Washington
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2300450&HistoricalAwards=false
• 关键词: Corps; novel; catheter; interventional; cardiology

The broader impact/commercial potential of this I-Corps project is the development of a catheter that will reduce surgery time, and thereby reduce the physicians’ and patients’ radiation exposure, and improve their long-term health. Over one million procedures to treat cardiovascular diseases, the leading causes of death and disability, are performed annually in the United States. Given these procedures' life-threatening and time-sensitive nature, there is intense pressure to reduce the procedure time and increase cardiac catheterization lab operational efficiency to expand patient access. Currently, physicians spend between 30 minutes to 4 hours on a patient, depending on the complexity of the cardiovascular procedure. Existing catheterization tools offer limited dexterity and control when navigating patient anatomy, forcing physicians to work with multiple catheters and guidewires of different shapes and sizes. These devices also lack distal tip control making it stressful to predict catheter response while navigating them inside a patient's vascular tree.This I-Corps project is based on the development of a novel metamaterial-based catheter that easily navigates through challenging anatomies and, unlike existing solutions, works on a beating heart. The invention involves the development of new metamaterial structures leading to material and structural behavior that would improve catheter navigation through tortuous patient anatomies, with physicians having absolute control over catheter behavior in surgeries on beating hearts. With this technology, physicians can dynamically alter the distal tip stiffness and lock catheter shapes, which is impossible with any existing solutions on the market. These metamaterial properties remove the need for using multiple catheters of different shapes and sizes for a single surgery leading to a better surgical procedure. This innovation has the potential to advance the field of interventional cardiology by removing procedural redundancies leading to higher efficacy and conception of novel catheter-based surgeries for diseases where patients are rejected for specific surgeries either due to complicated anatomies or lack of better surgical tools.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛影响/商业潜力是开发一种导管，该导管将减少手术时间，从而减少医生和患者的辐射暴露，并改善他们的长期健康。在美国，每年进行超过一百万例治疗心血管疾病的手术，心血管疾病是死亡和残疾的主要原因。考虑到这些手术的生命威胁和时间敏感性，存在减少手术时间和提高心导管插入术实验室操作效率以扩大患者访问的巨大压力。目前，医生花在病人身上的时间在30分钟到4小时之间，这取决于心血管手术的复杂性。现有的导管插入工具在导航患者解剖结构时提供有限的灵活性和控制，迫使医生使用不同形状和尺寸的多个导管和导丝。这些设备还缺乏远端尖端控制，这使得在患者血管树内导航时预测导管反应变得非常困难。I-Corps项目基于一种新型超材料导管的开发，该导管可以轻松导航通过具有挑战性的解剖结构，与现有解决方案不同，它可以在跳动的心脏上工作。本发明涉及新的超材料结构的开发，该超材料结构导致材料和结构行为，该材料和结构行为将改善导管通过曲折的患者解剖结构的导航，其中医生在跳动的心脏上的手术中对导管行为具有绝对控制。通过该技术，医生可以动态改变远端头端刚度并锁定导管形状，这是市场上任何现有解决方案都无法实现的。这些超材料特性消除了对于单次手术使用不同形状和尺寸的多个导管的需要，从而导致更好的外科手术。这项创新有可能通过消除程序冗余来推进介入心脏病学领域，从而提高新型导管的有效性和概念。该奖项反映了NSF的法定使命，并通过使用基金会的智力价值进行评估，更广泛的影响审查标准。